The protocol testing the ability to recognise, remember and distinguish between odours was able to identify older individuals who - according to genetic, imaging and more detailed memory tests - were at increased risk of Alzheimer's disease.
"There is increasing evidence that the neurodegeneration behind Alzheimer's disease starts at least 10 years before the onset of memory symptoms," said Mark Albers from Massachusetts General Hospital (MGH) in the US.
"The development of a digitally-enabled, affordable, accessible and non-invasive means to identify healthy individuals who are at risk is a critical step to developing therapies that slow down or halt Alzheimer's disease progression," said Albers.
After experiencing each odour for two seconds, they are asked whether the scent is familiar and then asked to choose among four words - from the names listed above - for the one that best describes the odour.
Participants then complete the Odour Awareness Scale (OAS), a previously validated questionnaire that assesses their overall attention to environmental odours and how they are affected emotionally and behaviourally by scents.
Participants are first asked whether a presented odour was included in the OPID-10 test and then asked which word best describes the odour.
Their ability to remember odours from the first test determines their POEM (Percepts of Odour Episodic Memory) score.
In the Odour Discrimination (OD) test, participants are presented with two consecutive odours and asked whether they were different or the same, a process that is repeated 12 times with different paired scents.
At the time of the olfactory testing, 70 were cognitively normal, 74 tested normal on cognitive tests but were personally concerned about their cognitive abilities, 29 had mild cognitive impairment and 10 had been diagnosed with possible or probable Alzheimer's disease.
Participant's ability to remember a previously presented aroma, as reflected in the POEM score, also showed significant differences between the two cognitively normal groups and participants with Alzheimer's disease, whose results were no better than chance.
The study was published in the journal Annals of Neurology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
